Elamipretide (SS-31) Becomes the First Cardiolipin-Directed Mitochondrial Drug Approved

According to the sponsor and contemporaneous reporting, on September 19, 2025 the U.S. Food and Drug Administration granted accelerated approval to elamipretide hydrochloride — the compound known in the research literature as SS-31 and MTP-131 (and earlier referenced as Bendavia) — under the brand name FORZINITY. The sponsor is Stealth BioTherapeutics. Per those sources, this is the first time a cardiolipin-targeting mitochondrial peptide has carried an FDA marketing authorization, and the sponsor describes it as the first FDA-approved mitochondria-targeted therapeutic. Researchers should confirm the regulatory specifics against primary FDA documents.

The reported approval is narrow. The described labeled indication for FORZINITY is to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg, as an injectable product. The authorization does not extend to the broader list of conditions in which SS-31 has been studied over the past decade, and the accelerated pathway carries a confirmatory-trial obligation (see below). This is reported as a regulatory fact, not as usage guidance.

FORZINITY is the trade name reported for the approved elamipretide HCl drug product. Barth syndrome — the disorder the product is indicated for — is described as an ultra-rare X-linked condition caused by pathogenic variants in the TAFAZZIN gene. Those variants disrupt the remodeling of cardiolipin, a signature phospholipid of the inner mitochondrial membrane, leaving cells with reduced and structurally abnormal cardiolipin and impaired mitochondrial energetics. Available sources characterize the condition as ultra-rare, affecting a small number of identified individuals predominantly among males; exact prevalence figures vary by source and should be verified against a primary registry.

The mechanistic link is what makes the approval notable for peptide chemistry: a drug whose entire rationale is binding cardiolipin reached market in a disease defined by a cardiolipin defect. That alignment between chemical target and disease biology is the substance of the 'first cardiolipin-directed' description used by the sponsor and in reporting.

Elamipretide is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine and the C-terminus is amidated. It belongs to the Szeto-Schiller (SS) class of mitochondria-targeting peptides, hence the research designation SS-31. Its alternating aromatic and basic residues give it the defining 'aromatic-cationic' character that drives its subcellular targeting.

The two basic residues (D-arginine and lysine) supply a net positive charge, while the two aromatic residues (dimethyltyrosine and phenylalanine) contribute hydrophobic, π-electron-rich rings. The D-arginine and amidated terminus are reported to reduce susceptibility to peptidase cleavage relative to an all-L analogue. This amphipathic, charge-shielded architecture is central to how the molecule is described as reaching and binding its target.

Cardiolipin is a dimeric, anionic phospholipid concentrated almost exclusively in the inner mitochondrial membrane, where it shapes membrane curvature and helps organize the respiratory chain. According to peer-reviewed reviews, elamipretide associates with cardiolipin through two simultaneous interactions: electrostatic attraction between its cationic residues and cardiolipin's negatively charged phosphate head groups, and hydrophobic contact between its aromatic side chains and the lipid acyl chains.

A distinguishing feature reported in the literature is that this targeting does not depend on the mitochondrial membrane potential. Many mitochondria-directed small molecules accumulate by chasing the membrane's negative interior, so they fail when that potential collapses — a condition seen in dysfunctional mitochondria. Because elamipretide's localization is described as driven by cardiolipin affinity rather than potential-driven uptake, it is reported to reach compromised mitochondria. Once bound, the peptide is described in preclinical work as stabilizing cristae architecture and supporting the assembly and stability of respiratory chain complexes, associated with more efficient electron transfer and reduced electron leak. These are mechanistic and preclinical characterizations, not claims of clinical effect.

• Reported target: cardiolipin on the inner mitochondrial membrane.
• Reported binding mode: combined electrostatic (cationic residues) and hydrophobic (aromatic residues) interactions.
• Distinctive trait described in the literature: localization independent of mitochondrial membrane potential.
• Reported structural effect (preclinical): stabilization of cristae and respiratory supercomplex organization.

'First-in-class' and 'first cardiolipin-directed' — as used by the sponsor and in reporting — refer to the regulatory milestone, not to novelty of the molecule itself, which has appeared in the research literature for well over a decade. The claim is that no prior FDA-approved drug has used direct cardiolipin association on the inner mitochondrial membrane as its primary mechanism. If accurate, it establishes a new mechanistic category in the approved-drug landscape, which is why it draws attention from researchers tracking mitochondrial pharmacology.

The 'first' framing is mechanism-specific. It does not imply broad efficacy across mitochondrial diseases, and it should not be read as validation for any non-approved context. The authorization is reported to be anchored to a single ultra-rare indication.

According to reporting, the Barth syndrome approval rested largely on TAZPOWER (NCT03098797), a randomized, double-blind, placebo-controlled crossover trial described as enrolling 12 genetically confirmed patients, followed by an open-label extension. As reported, TAZPOWER did not meet its co-primary endpoints (six-minute walk distance and total fatigue score) in the blinded crossover phase. The accelerated approval was instead reported to be supported by improvement in knee extensor muscle strength — an intermediate clinical endpoint — observed over the longer open-label extension. Under the accelerated approval framework, continued approval may be contingent on verification of clinical benefit in confirmatory trial(s). Patient counts and endpoint specifics should be confirmed against the primary trial record and FDA review.

This followed earlier setbacks in larger programs. In primary mitochondrial myopathy, the phase 3 MMPOWER-3 trial did not meet its co-primary endpoints (six-minute walk test and a fatigue measure), though post hoc genotype analyses were reported to suggest possible effects in specific subgroups. In age-related macular degeneration, a geographic-atrophy study (reported as ReCLAIM-2) has also been reported to miss its primary endpoints; this specific outcome is not backed by a citation in this article and should be independently verified. The Barth syndrome authorization is therefore best understood as a precision result in an ultra-rare, mechanistically matched indication rather than broad validation of the molecule.

SS-31 has circulated for years as a research compound, and the FORZINITY approval sharpens the distinction between an FDA-approved drug product manufactured to pharmaceutical standards and material supplied for laboratory research use. The two are not interchangeable: an approved injectable has a defined identity, purity specification, and regulated supply chain, whereas research-grade SS-31 is supplied under research-use-only terms with quality that varies by source. For laboratory researchers, an approval does not change the regulatory status of research-use-only material, and identity and purity still require independent verification on a per-batch basis.

According to its sponsor and contemporaneous reporting, the FDA granted accelerated approval to elamipretide HCl (FORZINITY) on September 19, 2025, described as the first FDA-approved mitochondria-targeted therapeutic. Researchers should confirm against primary FDA documents.

The reported labeled indication is to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. Barth syndrome is an ultra-rare disorder caused by TAFAZZIN gene variants that disrupt cardiolipin. This is reported here as a regulatory fact only; ChemVerify does not provide medical, dosing, or administration guidance.

They share the same active molecule (elamipretide / SS-31), but they are not equivalent products. FORZINITY is an FDA-approved drug product made to pharmaceutical specifications, while research-grade SS-31 is supplied for laboratory research use only, with identity and purity that vary by vendor and require independent verification.

It is reported to associate with cardiolipin on the inner mitochondrial membrane through combined electrostatic and hydrophobic interactions. Its cationic, aromatic structure is described as enabling localization that does not depend on the mitochondrial membrane potential, distinguishing it from many other mitochondria-directed compounds.

Because, per the sponsor and reporting, no prior FDA-approved drug used direct cardiolipin association on the inner mitochondrial membrane as its primary mechanism of action. The 'first-in-class' label refers to that regulatory and mechanistic milestone, not to the novelty of the molecule, which has been studied for over a decade.

It is reported to be an accelerated approval based on an intermediate endpoint (knee extensor muscle strength). Under the accelerated framework, continued approval may be contingent on verification of clinical benefit in confirmatory trial(s).

• FDA Peptide Reclassification 2026: 14 Peptides Return to Category 1 -> /learn/fda-peptide-reclassification-2026-14-peptides-return-to-category-1
• Are Research Peptides Legal? -> /learn/are-research-peptides-legal
• Research-Use-Only (RUO) Legal Status for Peptides: Complete Guide -> /learn/research-use-only-ruo-legal-status-for-peptides-complete-guide
• Verify a Peptide Batch (COA Check) -> /verify
• Compare Peptide Sources and Prices -> /compare